[go: up one dir, main page]

MX2010004291A - Producto de dispersion solida de farmacos basados en n-aril urea. - Google Patents

Producto de dispersion solida de farmacos basados en n-aril urea.

Info

Publication number
MX2010004291A
MX2010004291A MX2010004291A MX2010004291A MX2010004291A MX 2010004291 A MX2010004291 A MX 2010004291A MX 2010004291 A MX2010004291 A MX 2010004291A MX 2010004291 A MX2010004291 A MX 2010004291A MX 2010004291 A MX2010004291 A MX 2010004291A
Authority
MX
Mexico
Prior art keywords
solid dispersion
dispersion product
aryl urea
based drugs
solvent
Prior art date
Application number
MX2010004291A
Other languages
English (en)
Inventor
Rudolf Schroeder
Tanja Heitermann
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MX2010004291A publication Critical patent/MX2010004291A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto de dispersión sólida que comprende al menos un agente con actividad farmacéutica basado en N-aril urea que se obtiene mediante a) la preparación de una mezcla líquida que contiene al menos un agente activo, al menos un agente formador de matriz farmacéuticamente aceptable, al menos un agente tensoactivo farmacéuticamente aceptable y al menos un solvente, y b) la eliminación de los uno o más solventes de la mezcla líquida, para obtener el producto de dispersión sólida.
MX2010004291A 2007-10-19 2008-10-17 Producto de dispersion solida de farmacos basados en n-aril urea. MX2010004291A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961807P 2007-10-19 2007-10-19
PCT/EP2008/064076 WO2009050291A2 (en) 2007-10-19 2008-10-17 Solid dispersion product of n-aryl urea-based drugs

Publications (1)

Publication Number Publication Date
MX2010004291A true MX2010004291A (es) 2010-08-02

Family

ID=40089463

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004291A MX2010004291A (es) 2007-10-19 2008-10-17 Producto de dispersion solida de farmacos basados en n-aril urea.

Country Status (18)

Country Link
EP (1) EP2197425A2 (es)
JP (1) JP2011500649A (es)
KR (1) KR20100087170A (es)
CN (1) CN101827584A (es)
AU (1) AU2008313622A1 (es)
BR (1) BRPI0818340A2 (es)
CA (1) CA2699301A1 (es)
CO (1) CO6270206A2 (es)
CR (1) CR11442A (es)
DO (1) DOP2010000117A (es)
EC (1) ECSP10010183A (es)
GT (1) GT201000102A (es)
MX (1) MX2010004291A (es)
PA (1) PA8800101A1 (es)
RU (1) RU2010119929A (es)
UA (1) UA100865C2 (es)
WO (1) WO2009050291A2 (es)
ZA (1) ZA201002095B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
WO2011156361A2 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Solid dispersions containing kinase inhibitors
AU2012335663B2 (en) 2011-11-11 2015-12-24 Array Biopharma Inc. Method of treating a proliferative disease
AR088936A1 (es) 2011-11-23 2014-07-16 Novartis Ag Formulaciones farmaceuticas
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
WO2008055966A1 (en) * 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
PA8800101A1 (es) 2009-05-15
JP2011500649A (ja) 2011-01-06
GT201000102A (es) 2012-03-12
ZA201002095B (en) 2011-11-30
RU2010119929A (ru) 2011-11-27
EP2197425A2 (en) 2010-06-23
BRPI0818340A2 (pt) 2015-04-22
ECSP10010183A (es) 2010-06-29
WO2009050291A2 (en) 2009-04-23
CN101827584A (zh) 2010-09-08
KR20100087170A (ko) 2010-08-03
DOP2010000117A (es) 2010-05-15
CO6270206A2 (es) 2011-04-20
CR11442A (es) 2010-09-06
UA100865C2 (ru) 2013-02-11
CA2699301A1 (en) 2009-04-23
WO2009050291A3 (en) 2010-04-08
AU2008313622A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
UA100866C2 (ru) Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины
MX2010004291A (es) Producto de dispersion solida de farmacos basados en n-aril urea.
CR9292A (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2010121177A3 (en) Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2010021607A3 (en) Pharmaceutical formulation
PL2046292T3 (pl) Preparaty eterów benzymidazolilo-pirydylowych
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
NZ602441A (en) A fast dissolving pharmaceutical composition
WO2009060952A1 (ja) 新規製剤
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2012024605A3 (en) Devices and methods for intravaginal delivery of drugs and other substances
WO2008084864A1 (ja) カプサイシン受容体活性化剤及びそれを噴霧する装置
WO2010058104A3 (fr) Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
WO2008129607A1 (ja) ヒアルロナン産生促進剤及びヒアルロナン分解抑制剤
WO2011002424A3 (en) Solubility and stability enchancing pharmaceutical formulation comprising ezetimibe and simvastatin
CO6270249A2 (es) Fibra, pelicula o espuma que comprende un plastificador y un gel ligado a arcilla cargado y metodos para su produccion
MY148088A (en) Stable nanoparticle formulations
TH104743A (th) ผลิตภัณฑ์แพร่กระจายแข็งที่มีสารประกอบ n-อะริล ยูเรีย
WO2011154830A3 (es) Forma farmaceutica de inhibidores de la fosfodiesterasa para administracion transmucosa
HK1164692A (en) Controlled release pharmaceutical or food formulation and process for its preparation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal